Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

This is a multicenter, randomized, parallel group, double-masked, active- controlled study.
Subjects will be enrolled and randomized to either 8 % or 15% DSP-Visulex with placebo drops
or Vehicle-Visulex (V-Visulex) with prednisolone acetate 1% eye drops. All subjects will
receive concomitant treatment with cyclopentolate.

Inclusion Criteria:

- Non-infectious anterior uveitis

Exclusion Criteria:

- lntraocular pressure > 25mm Hg OU.

- Previous occurrence of an acute episode of anterior uveitis in affected eye(s) within
4 weeks prior to Visit 1.

- Historical or active intermediate or posterior uveitis in affected eye(s).

- Clear systemic causes of uveitis that may require or have required systemic treatment

- Uveitis suspected to have resulted from recent surgery or trauma.

- Use of ocular medication of any kind in affected eye(s) more than 2 days prior to
Visit 1, excluding artificial tears, topical allergy medications, eyelid scrubs.

- Current use, or anticipated initiation during the study, of a corticosteroid or an
immunosuppressant agent by any route (oral, inhaled, ocular, dermal). Current stable
use is allowed.